Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment-Reference-Cited by-同舟云学术

Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment

Published:2023-11-03 Issue:6 Volume:26 Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Mimura Shima¹,Fujita Koji¹,Takuma Kei¹,Nakahara Mai¹,Oura Kyoko¹,Tadokoro Tomoko¹,Tani Joji¹,Morishita Asahiro¹,Ono Masafumi¹,Himoto Takashi²,Masaki Tsutomu¹

Affiliation:

1. Department of Gastroenterology and Neurology, Kagawa University Hospital, Kita, Kagawa 761‑0793, Japan

2. Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761‑0123, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Reference26 articles.

1. Are published health economic models for chronic hepatitis B appropriately capturing the benefits of HBsAg Loss? A systematic literature review;Wigfield;Pharmacoecon Open,2020

2. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update;Sarin;Hepatol Int,2019

3. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely;Chevaliez;J Hepatol,2013

4. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss;Zoutendijk;J Infect Dis,2011

5. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B;Boni;J Hepatol,2003

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up;Internal Medicine;2024